• Founded in 2016

Description :

Zelluna Immunotherapy is a company dedicated to the development of innovative immunotherapies for the treatment of a broad range of cancers with a high unmet medical need. The company’s core asset consists of a large panel of tumour specific T cell receptors (TCRs) isolated from long-term survivors from cancer vaccine trials that can be used in multiple therapeutic settings.

Headquarters :

Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, 0379 Oslo

Related Posts

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.